CellWell record HH-621106
[A Case of EGFR-mutant Lung Adenocarcinoma with Secondary SCLC Transformation and ALK Fusion after Osimertinib Treatment]
Liyan Liao; Xiaohong Li
2026
In plain language
In one patient with EGFR-mutant lung adenocarcinoma, first-line EGFR-targeted therapy was followed by small cell transformation and an ALK fusion, suggesting both resistance mechanisms can coexist.
- Evidence
- Emerging
- Design
- Case report
Cite this record: https://thecellwell.org/studies/HH-621106
Produced by the CellWell Research Engine, custom software owned and operated by CellWell and The Holistic Hub. All rights reserved. This analysis, its indexing and its evidence classifications are proprietary. Any use, republication or onward sharing must credit CellWell Research Engine (thecellwell.org) as the source.
This is an educational research library, not medical advice. Nothing here may be used to diagnose, treat, cure, or prevent any disease. Always consult a qualified professional.